Mr. Zhang was appointed as an independent non-executive director on June 2020. Mr. Zhang, as a Chinese Certified Public Accountant and Senior Accountant, graduated in accounting from Jiangxi University of Finance and Economics, the PRC in July 1985, and graduated in law from Party School of the Central Committee of C.P.C in December 2001. Mr. Zhang previously worked at the Industry and Transport Division of the Department of Finance of Jiangsu Province, Jiangsu High and New Technology Venture Capital Company, Jiangsu Assets and Equity Exchang and Jiangsu Asset Appraisal Company. Also he served as the director of Jiangsu Certified Public Accountants Company, was the director of the asset appraisal center under the Department of Finance of Jiangsu Province and held the division chief of Jiangsu Rural Comprehensive Reform Working Group Office.

Mr. Tang has served as a non-executive director of the company since May 2015. Mr. Tang obtained his bachelor’s double degree in mechanical engineering and business management from Huaqiao University. Mr. Tang's main experience includes: from 1991 to 1993, he served as a department manager of Shenzhen Shekou Foreign Economic Development Company; from 1993 to 1996, he served as the general manager of Shenzhen Yuesi Industrial Co., Ltd; since 1996, he has been the chairman of the board of directors at Shenzhen Finevalue Technology Co., Ltd.; since April 2013, he has served as the director of Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.; since July 2013, he has been appointed representative of the executive affairs partner of Suzhou Ruiyuan Shengben Biomedical Management Partnership (Limited Partnership); since July 2017, he has been the chairman of the board of directors of Jiangsu Xinyun Capital Management Co., Ltd.

Mr. Qian was appointed as an independent non-executive director on June, 2018. Mr. Qian obtained his bachelor of laws degree from Fudan University and master of laws degree from Nanjing University. Mr. Qian previously worked at Jiangsu Law School, Nanjing Xiemanlin Law Firm and Jiangsu Weishide Law Firm; since March 2006, he has been a lawyer and is currently a partner at Jiangsu Gowin Law Firm. Mr. Qian has been an arbitrator under the Nanjing Arbitration Committee since September 2017 and was employed as a legal consultant of the Nanjing People’s Government in December 2017.

Dr. Feng was appointed as an independent non-executive director from November 2021. Dr. Feng obtained his bachelor’s degree in medicine from Shanghai First Medical College (now known as Shanghai Medical College of Fudan University) in December 1982 and a doctor’s degree in diagnostic radiology in December 1988. He served as the deputy dean and secretary of the Party Committee at Huashan Hospital of Fudan University from April 2000 to May 2008. From May 2007 to June 2011, he served as the dean of Shanghai Medical College of Fudan University. He served as the vice president of Fudan University from May 2011 to July 2015 and since August 2016, he served as a tenured professor at Huashan Hospital of Fudan University. He has been appointed as the chairman of Lunqin (Shanghai) Medical Technology Co., Ltd since November 2016. He served as the dean of Shanghai Penta Innovation & Entrepreneurship Institute since January 2018. He also served as the president of Shanghai Society of Biotechnology since October 2018.

Mr. Xiong is the chairman of the board, executive director and the legal representative of our company. He is responsible for the overall management, implementing decisions and operations of the Company. Mr. Xiong obtained his bacherlor's degree in investment economics management from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) and MBA from the Chinese University of Hong Kong. Mr.Xiong has more than 20 years of experience in pharmaceutical investment and management of pharmaceutical enterprises. Mr. Xiong had perviously worked at Guolian Fund Management Co., Ltd., Shanghai Union Biopharm.Co., Ltd., and etc. Now Mr.Xiong acts as the chairman of the Company, and executive director, chairman and general manager of several subsidiaries of the Company, and executive director of Shanghai Baoying Asset Management Co., Ltd.

Mr. Qian was appointed as an independent non-executive director on June, 2018. Mr. Qian obtained his bachelor of laws degree from Fudan University and master of laws degree from Nanjing University. Mr. Qian previously worked at Jiangsu Law School, Nanjing Xiemanlin Law Firm and Jiangsu Weishide Law Firm; since March 2006, he has been a lawyer and is currently a partner at Jiangsu Gowin Law Firm. Mr. Qian has been an arbitrator under the Nanjing Arbitration Committee since September 2017 and was employed as a legal consultant of the Nanjing People’s Government in December 2017.

Mr. Zhang was appointed as an independent non-executive director on June 2020. Mr. Zhang, as a Chinese Certified Public Accountant and Senior Accountant, graduated in accounting from Jiangxi University of Finance and Economics, the PRC in July 1985, and graduated in law from Party School of the Central Committee of C.P.C in December 2001. Mr. Zhang previously worked at the Industry and Transport Division of the Department of Finance of Jiangsu Province, Jiangsu High and New Technology Venture Capital Company, Jiangsu Assets and Equity Exchang and Jiangsu Asset Appraisal Company. Also he served as the director of Jiangsu Certified Public Accountants Company, was the director of the asset appraisal center under the Department of Finance of Jiangsu Province and held the division chief of Jiangsu Rural Comprehensive Reform Working Group Office.

Mr. Xiong is the chairman of the board, executive director and the legal representative of our company. He is responsible for the overall management, implementing decisions and operations of the Company. Mr. Xiong obtained his bacherlor's degree in investment economics management from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) and MBA from the Chinese University of Hong Kong. Mr.Xiong has more than 20 years of experience in pharmaceutical investment and management of pharmaceutical enterprises. Mr. Xiong had perviously worked at Guolian Fund Management Co., Ltd., Shanghai Union Biopharm.Co., Ltd., and etc. Now Mr.Xiong acts as the chairman of the Company, and executive director, chairman and general manager of several subsidiaries of the Company, and executive director of Shanghai Baoying Asset Management Co., Ltd.

Dr.Li is our chief executive officer and general manager since 2018 and is responsible for formulating business strategies and managing operation of the Company. Dr.Li obtained B.S in public health, master's degree in medicine from Shanghai Medical College of Fudan University, and Ph.D in preventive medicine from University of Iowa. Prior to Junshi, he held various positions, including team leader of the Office of Biostatistics, team leader of mathematical statistician and a statistical reviewer at the FDA , then he was employed by Sanofi in which he acted as Vice President Asia Regulatory Affairs in Global Regulatory Affairs. Dr. Li was a part-time professor or guest professor at Johns Hopkins University, the Clinical Research Institute of Peking University, the Medical Informatics Center of Peking University,respectively from 2007 to 2014.

Dr. Feng was appointed as an independent non-executive director from November 2021. Dr. Feng obtained his bachelor’s degree in medicine from Shanghai First Medical College (now known as Shanghai Medical College of Fudan University) in December 1982 and a doctor’s degree in diagnostic radiology in December 1988. He served as the deputy dean and secretary of the Party Committee at Huashan Hospital of Fudan University from April 2000 to May 2008. From May 2007 to June 2011, he served as the dean of Shanghai Medical College of Fudan University. He served as the vice president of Fudan University from May 2011 to July 2015 and since August 2016, he served as a tenured professor at Huashan Hospital of Fudan University. He has been appointed as the chairman of Lunqin (Shanghai) Medical Technology Co., Ltd since November 2016. He served as the dean of Shanghai Penta Innovation & Entrepreneurship Institute since January 2018. He also served as the president of Shanghai Society of Biotechnology since October 2018.

Mr. Qian was appointed as an independent non-executive director on June, 2018. Mr. Qian obtained his bachelor of laws degree from Fudan University and master of laws degree from Nanjing University. Mr. Qian previously worked at Jiangsu Law School, Nanjing Xiemanlin Law Firm and Jiangsu Weishide Law Firm; since March 2006, he has been a lawyer and is currently a partner at Jiangsu Gowin Law Firm. Mr. Qian has been an arbitrator under the Nanjing Arbitration Committee since September 2017 and was employed as a legal consultant of the Nanjing People’s Government in December 2017.

Mr. Xiong is the chairman of the board, executive director and the legal representative of our company. He is responsible for the overall management, implementing decisions and operations of the Company. Mr. Xiong obtained his bacherlor's degree in investment economics management from Zhongnan University of Economics (now known as Zhongnan University of Economics and Law) and MBA from the Chinese University of Hong Kong. Mr.Xiong has more than 20 years of experience in pharmaceutical investment and management of pharmaceutical enterprises. Mr. Xiong had perviously worked at Guolian Fund Management Co., Ltd., Shanghai Union Biopharm.Co., Ltd., and etc. Now Mr.Xiong acts as the chairman of the Company, and executive director, chairman and general manager of several subsidiaries of the Company, and executive director of Shanghai Baoying Asset Management Co., Ltd.

Dr.Li is our chief executive officer and general manager since 2018 and is responsible for formulating business strategies and managing operation of the Company. Dr.Li obtained B.S in public health, master's degree in medicine from Shanghai Medical College of Fudan University, and Ph.D in preventive medicine from University of Iowa. Prior to Junshi, he held various positions, including team leader of the Office of Biostatistics, team leader of mathematical statistician and a statistical reviewer at the FDA , then he was employed by Sanofi in which he acted as Vice President Asia Regulatory Affairs in Global Regulatory Affairs. Dr. Li was a part-time professor or guest professor at Johns Hopkins University, the Clinical Research Institute of Peking University, the Medical Informatics Center of Peking University,respectively from 2007 to 2014.

Dr. Meng was appointed as an independent non-executive director on June 2023. Dr. Meng received a bachelor’s degree in agronomy from
Southwest Agricultural University* (西南農業大學) in July 1983, and a doctorate degree in genetics from the University of Nottingham in November 1990. He was elected as an academician of the Chinese Academy of Sciences in 2007 and an academician of The World Academy of Sciences for the advancement of science in developing countries in 2008. From December 1990 to December 1992, he worked as a postdoctoral researcher at the School of Biology, China Agricultural University. From December 1992 to August 1998, he served as an associate professor at the School of Biology, China Agricultural University, during which from March 1996 to August 1998, he was a visiting scholar at the Institute of Molecular Medicine and Genetics, Medical College of Georgia in the United States. Since August 1998, he has been a professor at the School of Life Sciences, Tsinghua University.

Mr. Zhang was appointed as an independent non-executive director on June 2020. Mr. Zhang, as a Chinese Certified Public Accountant and Senior Accountant, graduated in accounting from Jiangxi University of Finance and Economics, the PRC in July 1985, and graduated in law from Party School of the Central Committee of C.P.C in December 2001. Mr. Zhang previously worked at the Industry and Transport Division of the Department of Finance of Jiangsu Province, Jiangsu High and New Technology Venture Capital Company, Jiangsu Assets and Equity Exchang and Jiangsu Asset Appraisal Company. Also he served as the director of Jiangsu Certified Public Accountants Company, was the director of the asset appraisal center under the Department of Finance of Jiangsu Province and held the division chief of Jiangsu Rural Comprehensive Reform Working Group Office.

Dr. Herbst was appointed as an independent non-executive director on June 24, 2018. Dr. Herbst was a Clinical Fellow from 1991 to 1994 at Harvard Medical School; he held various positions at the University of Texas M.D. Anderson Cancer Center (UT-MDACC) from 1998 to 2011, including the Barnhart Family Distinguished Professor of Targeted Therapy, Professor of Cancer Biology, and the Chief of Section of Thoracic Medical Oncology at the Department of Thoracic/Head and Neck Medical Oncology; since March 2011, he has held various positions at Yale University, including Ensign Professor of Medicine (Medical Oncology), Professor of Pharmacology, Professor of Medicine, Chief of Medical Oncology at Yale Cancer Center, leader of the Clinical Research Program in Phase I Cancers at Smilow Cancer Hospital, Associate Director for Translational Research at the Yale Cancer Center and leader of Disease Aligned Research Team in the Thoracic Oncology Program at the Yale Cancer Center.
Dr. Herbst obtained his M.S. degree from Yale University, the United States in June 1984, his Ph.D. in Molecular Cell Biology from The Rockefeller University, the United States in June 1990, his M.D. degree in Medicine from Cornell University Medical College, the United States in May 1991, his M.S. degree from Harvard University, the United States in November 1997 and an Honorary M.A. degree from Yale University in December 2012.